Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Khiron Life Sciences Corp. (V:KHRN)

Business Focus: Alternative Medicine

Sector:  Healthcare Industry:  Pharmaceuticals
See Regulatory Filings on SEDAR
Company Contact
Address: 100 King St.W.
Suite 1600, 1 First Canadian Place
Tel: 1-833-2758984
IR: See website
Key People
Chris Naprawa
Chairman of the Board
Alvaro Torres
Chief Executive Officer, Director
Helen Bellwood
Interim Chief Financial Officer
Franziska Katterbach
President, Khiron Europe
Juan Diego Alvarez
Vice President, Regulatory Affairs
Manuel Buendia
Vice President, Operations
Rodrigo Duran
Vice President, Pharma
Business Overview
Khiron Life Sciences Corp. (Khiron) is a vertically integrated international medical cannabis company with core operations in Latin America and Europe. The Company's product lines include medical cannabis products, health services and wellbeing products. The medical cannabis product sells branded medical cannabis products. The health service operates its own network of medium complexity health centers (operating under the ILANS and Zerenia brands) and Zerenia satellite clinics offering a range of health, medical and surgical services in alignment with insurance company partners. Its wellbeing product is focused on delivering the benefits of cannabidiol (CBD) a range of various branded consumer packaged goods, such as its Kuida cosmetics line. The Company provides patient-oriented approach, physician education programs, scientific expertise, product innovation, and agricultural infrastructure. The Company sells its products in Colombia, Peru, Germany, United Kingdom and Brazil.
Financial Overview
For the nine months ended 30 September 2022, Khiron Life Sciences Corp revenues increased 36% to C$12.5M. Net loss decreased 18% to C$11.2M. Revenues reflect Medical cannabis increase from C$2.6M to C$6.9M. Lower net loss reflects Corporate governance decrease of 75% to C$651K (expense), Share-based compensation decrease of 62% to C$975K (expense), Office and general decrease of 33% to C$1.5M (expense).
Employees: 310 as of Dec 31, 2021
Reporting Currency: Canadian Dollars
Enterprise value: $5.33M as of Sep 30, 2022
Annual revenue (TTM): $16.14M as of Sep 30, 2022
EBITDA (TTM): -$16.86M as of Sep 30, 2022
Net annual income (TTM): -$30.66M as of Sep 30, 2022
Free cash flow (TTM): -$17.82M as of Sep 30, 2022
Net Debt Last Fiscal Year: $0.63M as of Sep 30, 2022
Shares outstanding: 218,609,396 as of Feb 3, 2023
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization